Creo Medical Group PLC Director/PDMR Shareholding (1445A)

TIDMCREO

RNS Number : 1445A

Creo Medical Group PLC

22 December 2017

Creo Medical Group plc

Director/PDMR Dealing

The Company announces that on 22 December 2017, Christopher Hancock, Chief Technology Officer, transferred ordinary shares from his personal holding to his self-invested personal pension (SIPP) via the sale of 36,716 ordinary shares at a price of 69.5p per share and the purchase of 36,664 ordinary shares at a price of 69.5p per share. Following these transactions, Mr Hancock's total interest in ordinary shares is 4,880,098 ordinary shares.

Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1    Details of the person discharging managerial 
       responsibilities / person closely associated 
---  ------------------------------------------------------------ 
 a)   Name                       Chris Hancock 
---  -------------------------  --------------------------------- 
 2    Reason for the notification 
---  ------------------------------------------------------------ 
 a)   Position/status            Chief Technology Officer 
---  -------------------------  --------------------------------- 
 b)   Initial notification       Initial 
       /Amendment 
---  -------------------------  --------------------------------- 
 3    Details of the issuer, emission allowance 
       market participant, auction platform, auctioneer 
       or auction monitor 
---  ------------------------------------------------------------ 
 a)   Name                       Creo Medical Group plc 
---  -------------------------  --------------------------------- 
 b)   LEI                        213800H188ZDCWWXFA21 
---  -------------------------  --------------------------------- 
 4    Details of the transaction(s): section to 
       be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) each 
       date; and (iv) each place where transactions 
       have been conducted 
---  ------------------------------------------------------------ 
 a)   Description of 
       the financial               Ordinary shares of GBP0.001 
       instrument, type            each 
       of instrument 
 
       Identification              GB00BZ1BLL44 
       code 
---  -------------------------  --------------------------------- 
 b)   Nature of the              Transfer of ordinary shares 
       transaction                to SIPP via sale and purchase 
---  -------------------------  --------------------------------- 
 c)   Price(s) and volume(s)       Price(s)            Volume(s) 
                                   ------------------  ---------- 
 
                                     Sale of shares 
                                     from personal 
                                     holding at 
                                     69.5p per share     36,716 
                                   ------------------  ---------- 
                                    Purchase by 
                                     SIPP at 69.5p 
                                     per share          36,664 
                                   ------------------  ---------- 
---  -------------------------  --------------------------------- 
 d)   Aggregated information 
 
       - Aggregated volume 
 
 
       - Price 
                                   Weighted average price of 
                                   69.5 pence per share 
---  -------------------------  --------------------------------- 
 e)   Date of the transaction    21 December 2017 
---  -------------------------  --------------------------------- 
 f)   Place of the transaction   London Stock Exchange 
---  -------------------------  --------------------------------- 
 

Contacts

 
 Creo Medical:                   Cenkos:             FTI Consulting: 
 Richard Rees                    Camilla Hume/Mark   Brett Pollard 
  [phone]             Connelly (NOMAD)    / Mo Noonan 
  [e-mail]    Michael Johnson     [phone] 
                                  / Russell Kerr      1000 
                                  (Sales)             [e-mail] 
                                  [phone] 
                                  8900 
 

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and radiowave energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides physicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring its CROMA platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing safer, less-invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, www.creomedical.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHLLFVDFFLLFID

(END) Dow Jones Newswires

December 22, 2017 04:24 ET (09:24 GMT)